Issa, G., Fathi, A., Zeidan, A., Erba, H., Roboz, G., Altman, J., Pratz, K., Juckett, M., Lin, T., Balasubramanian, S. K., Advani, A., Schiller, G., Palmisiano, N., Rotta, M., Strickland, S., McMahon, C., Madanat, Y., Badar, T., Khawandanah, M., Yaghmour, G., McCloskey, J., Mangan, J., Saliba, A., Gojo, I., Osman, D., Zhang, H., Tian, Y., Riches, M., Corum, D., Leoni, M., Wang, E. (2025). Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007. Blood. https://doi.org/10.1182/blood-2025-764